Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 4 , Pages 364-368 , April 2008

Complementary and Alternative Medicine (CAM) Treatments and Pediatric Psychopharmacology

,Accepted 17 October 2007.

REFERENCES 

  1. Wilson KM, Klein JD, Sesselberg TS, et al. Use of complementary medicine and dietary supplements among US adolescents. J Adolesc Health. 2006;38:385–394
  2. Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol. 2006;16:197–206
  3. Kemper KJ, O'Connor KG. Pediatricians' recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482–487
  4. Lopez-Munoz F, Bhatara VS, Alamo C, Cuenca E. Historical approach to reserpine discovery and its introduction in psychiatry. Actas Esp Psiquiatr. 2004;32:387–395
  5. Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California Poison Control System. Am J Health Syst Pharm. 2005;62:1476–1482
  6. Freeman MP, Hibbeln JR, Mischoulon D, et al. Omega-3 fatty acids: evidence for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954–1967
  7. Clayton EH, Hanstock TL, Garg ML, Hazell PL. Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents. Acta Neuropsychiatr. 2007;19:92–103
  8. Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust. 2006;185:368–372
  9. Linde K, Berner M, Egger M, Mulrow C. St. John's wort for depression. Meta-analysis of randomized controlled trials. Br J Psychiatry. 2005;186:99–107
  10. Ernst E. Second thoughts about safety of St. John's wort. Lancet. 1999;354:2014–2016
  11. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am. 2007;30:51–68
  12. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev. 2003;1:CD003383.
  13. Centers for Disease Control and Prevention . Hepatic toxicity possibly associated with kava-containing products-United States, Germany and Switzerland 1999-2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065–1067
  14. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11:131–142
  15. Jorm AF, Christensen H, Griffiths KM, Parslow RA, Rodgers B, Blewitt KA. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust. 2004;181:S29–S46
  16. Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26:363–367
  17. Cohen MH, Kemper KJ. Complementary therapies in pediatrics: a legal perspective. Pediatrics. 2005;115:774–781
  18. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006;163:1098–1100
  19. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev. 2006;3:CD001257.
  20. Hallaham B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomized controlled trial. Br J Psychiatry. 2007;190:118–122
  21. Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115:1360–1366
  22. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2006;61:551–553
  23. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230–1250

 Psychopharmacology Perspectives aims to discuss practical approaches to everyday issues in pediatric pharmacotherapy. The discussions may address aspects of clinical care related to psychopharmacology for which we do not have adequate applicable controlled trials. Given the need to address symptoms in youths with often complex, severe, and comorbid disorders, recommendations are likely to be off-label from the perspective of the U.S. Food and Drug Administration. We fully appreciate that for virtually all disorders, medication is only one aspect of comprehensive care. This column focuses primarily on psychopharmacological management. Although it is important that clinicians address psychosocial issues in the evaluation and treatment of their patients, such discussion is beyond the specific scope of this feature. These are not meant to be practice guidelines, but rather examples of the thought process that may go into pharmacotherapy decision-making.Disclosure: The authors report no conflicts of interest.

PII: S0890-8567(09)62390-X

doi: 10.1097/CHI.0b013e31816520e5

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 47, Issue 4 , Pages 364-368 , April 2008

Article Tools